Austin, MA (1998) Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 14, Suppl. B, 14b–17b.
Hokanson, JE & Austin, MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3, 213–219.
Liu, J, Zeng, FF, Liu, ZM, et al. (2013) Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 12, 159.
Valdivielso, P, Ramirez-Bueno, A & Ewald, N (2014) Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med 25, 689–694.
Kris-Etherton, PM, Harris, WS, Appel, LJ, et al. (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23, e20–30.
Caslake, MJ, Miles, EA, Kofler, BM, et al. (2008) Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 88, 618–629.
Thifault, E, Cormier, H, Bouchard-Mercier, A, et al. (2013) Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenomics 6, 73–82.
Minihane, AM, Khan, S, Leigh-Firbank, EC, et al. (2000) ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20, 1990–1997.
Minihane, AM (2010) Fatty acid-genotype interactions and cardiovascular risk. Prostaglandins Leukotrienes Essent Fatty Acids 82, 259–264.
Madden, J, Williams, CM, Calder, PC, et al. (2011) The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 31, 203–234.
Meisel, C, Gerloff, T, Kirchheiner, J, et al. (2003) Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med (Berl) 81, 154–167.
Cormier, H, Rudkowska, I, Paradis, AM, et al. (2012) Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation. Nutrients 4, 1026–1041.
Bookstein, L, Gidding, SS, Donovan, M, et al. (1990) Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. Arch Intern Med 150, 1653–1657.
Bhatt, DL, Steg, PG, Miller, M, et al. (2019) Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New Eng J Med 380, 11–22.
Wei, MY & Jacobson, TA (2011) Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 13, 474–483.
Allaire, J, Couture, P, Leclerc, M, et al. (2016) A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study. Am J Clin Nutr 104, 280–287.
Alberti, KG, Zimmet, P, Shaw, J, et al. (2005) The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062.
Pirro, M, Bergeron, J, Dagenais, GR, et al
. (2001) Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 161, 2474–2480.
Allaire, J, Vors, C, Tremblay, AJ, et al. (2018) High-dose DHA has more profound effects on LDL-related features than high-dose EPA: the ComparED study. J Clin Endocrinol Metab 103, 2909–2917.
Airlie, Lohman, T, Roche, A, et al. (1988) Standardization of anthropometric measurements. In The Airlie (VA) Concensus Conference, pp. 39–80. Champaign, IL: Human Kinetics.
Allaire, J, Harris, WS, Vors, C, et al. (2017) Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid. Prostaglandins Leukotrienes Essent Fatty Acids (PLEFA) 120, 8–14.
Jellinger, PS, Handelsman, Y, Rosenblit, PD, et al. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 23, 1–87.
Nicolas, JM, Espie, P & Molimard, M (2009) Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 41, 408–421.
Lamarche, B & Couture, P (2015) Dietary fatty acids, dietary patterns, and lipoprotein metabolism. Curr Opin Lipidol 26, 42–47.
Skulas-Ray, AC, Kris-Etherton, PM, Harris, WS, et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243–252.
Sirtori, CR, Tremoli, E, Sirtori, M, et al. (1977) Treatment of hypertriglyceridemia with metformin. Effectiveness and analysis of results. Atherosclerosis 26, 583–592.
Cottin, SC, Sanders, TA & Hall, WL (2011) The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 70, 215–231.
Bouchard-Mercier, A, Rudkowska, I, Lemieux, S, et al. (2013) Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation. J Lipid Res 54, 2866–2873.
Tremblay, BL, Cormier, H, Rudkowska, I, et al. (2015) Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial. Lipids Health Dis 14, 12.
Lindi, V, Schwab, U, Louheranta, A, et al. (2003) Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 79, 52–60.
Olano-Martin, E, Anil, E, Caslake, MJ, et al. (2010) Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 209, 104–110.
Rudkowska, I, Guenard, F, Julien, P, et al. (2014) Genome-wide association study of the plasma triglyceride response to an n-3 polyunsaturated fatty acid supplementation. J Lipid Res 55, 1245–1253.
Tavori, H, Rashid, S & Fazio, S (2015) On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 238, 264–270.
Cholesterol Treatment Trialists C, Mihaylova, B, Emberson, J, et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581–590.
Aung, T, Halsey, J, Kromhout, D, et al. (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 3, 225–234.
Abdelhamid, AS, Brown, TJ, Brainard, JS, et al. (2018) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, issue 7, CD003177.
Manson, JE, Cook, NR, Lee, IM, et al. (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New Eng J Med 380, 23–32.